Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
December 20, 2016
BioLife Solutions (BLFS) new supply client, TissueGene
December 20, 2016
Pluristem Therapeutics (PSTI) term sheet for new corporation in Japan to commercialize PLX-PAD for Critical Limb Ischemia (CLI)
December 15, 2016
Vericel (VCEL) proposes 6.2 M share $17 M offering at $2.75
December 14, 2016
Brainstorm Cell Therapeutics (BCLI) new data from its P2 study of NurOwn – SELL into strength
December 14, 2016
Kite Pharma (KITE) strategic partnership with Vitruvian Networks - BUY
December 14, 2016
Organovo ONVO) exclusive distributor agreement with Cosmo Bio (JASDAQ:3386) for its NovoView Preclinical Services in Japan - BUY
December 12, 2016
World Stem Cell Summit, a past week of cell therapy and regenerative medicine
December 12, 2016
Kite Pharma (KITE) characterizes of T cell receptor candidates
November 29, 2016
Vericel (VCEL) investor converts Series A Preferred Stock
November 23, 2016
Juno Therapeutics (JUNO) JCAR015 P2 ROCKET trial on HOLD,
November 22, 2016
Fate Therapeutics (FATE), a $13.30 preferred combined with a $2.66 per share private placement for proceeds of $57 M
November 22, 2016
Biostage (BSTG) the “spin” is on; NASDAQ issued a continued listing deficiency notice
November 16, 2016
ImmunoCellular Therapeutics (NYSE MKT: IMUC) reverses itself out of a NYSEMKT listing issue
November 2, 2016
Opexa Therapeutics (OPXA) reduces workforce by 40%
November 1, 2016
Caladrius BioSciences (CLBS) partner, Sanford Research in P2 Type 1 Diabetes trial extends agreement
November 1, 2016
Organovo (ONVO) multiple customer orders for preclinical product … BUY
November 1, 2016
Pluristem Therapeutics (PSTI) P3 of Critical Limb Ischemia (CLI) cleared in UK
October 28, 2016
Opexa (OPXA) P2b Tcelna trial failed to meet endpoints
October 27, 2016
TiGenix NV (Euronext Brussels: TIG) proposes U.S. IPO
October 24, 2016
Histogenics (HSGX), ups enrollment numbers
October 24, 2016
Aduro Biotech (ADRO) reports Clinical Hold to pause enrollment in LADD trials
October 21, 2016
Northwest Biotherapeutics (NWBO) proposes 14 M share RDO at $0.38 to raise $5 M
October 20, 2016
Capricor Therapeutics (CAPR) NIH grant of $4.2 M to Evaluate Exosomes for Hypoplastic Left Heart Syndrome
October 19, 2016
Organovo Holdings (ONVO) proposes 9 M share offering at $2.75 per share to raise $25 M
October 6, 2016
AxoGen (AXGN) proposes offering of 2.33 M shares priced at $7.50
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.